STUDY OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED TO THE STANDARD OF CARE (EXTREME STUDY REGIMEN) AS FIRST LINE TREATMENT IN PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK: